For: | Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288 [PMID: 26109816 DOI: 10.3748/wjg.v21.i23.7281] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i23/7281.htm |
Number | Citing Articles |
1 |
Nuttavut Sumransub, Kornpong Vantanasiri, Ajay Prakash, Emil Lou. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. Molecular Therapy - Oncolytics 2021; 22: 1 doi: 10.1016/j.omto.2021.05.001
|
2 |
Toshikazu Moriwaki, Masahiko Gosho, Akinori Sugaya, Takeshi Yamada, Yoshiyuki Yamamoto, Ichinosuke Hyodo. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. Cancer Research and Treatment 2021; 53(3): 703 doi: 10.4143/crt.2020.805
|
3 |
Yaping Chen, Xiao Zheng, Changping Wu. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.792691
|